CAR T细胞治疗NHL毒副作用临床管理专家共识  

Experts consensus on clinical management of toxicity associated withCAR T cell therapy in non-Hodgkin′s lymphoma(NHL)

作　　者：中国研究型医院学会生物治疗学专委会 韩为东[2] 梁爱斌[3] 钱文斌 刘洋[2] 李萍[5] 张亚晶[2] 史凤霞[2] 梁赟[6] Specialty Committee of Biotherapy,the Chinese Research Hospital Association(不详)

机构地区：[1]不详 [2]解放军总医院生物治疗科 [3]上海同济大学附属同济医院 [4]浙江大学医学院附属第二医院血液内科 [5]上海同济大学附属同济医院血液科 [6]浙江大学医学院附属第二医院血液科

出　　处：《转化医学杂志》2021年第1期1-11,共11页Translational Medicine Journal

摘　　要：嵌合抗原受体修饰T细胞(Chimeric Antigen Receptor T Cell,CAR T)已成为难治性复发B细胞非霍奇金淋巴瘤(Non-Hodgkin′s Lymphoma,NHL)的有效治疗手段,此背景下其毒副作用的临床处置规范化也势在必行。中国研究型医院学会生物治疗学专委会组织专家编写此共识于2020年11月完成,旨在为临床工作人员判别与处理CAR T细胞治疗NHL相关毒副作用提供更为全面、规范的处置原则和探索性处理建议。Chimeric antigen receptor T cell(CAR T cell)has been proved to be an promising approach to the treatment for refractory and relapsed B-cell non Hodgkin′s lymphoma(NHL).Consequently,it is necessary to standardize the clinical managements of toxicities with CAR T cell therapy.The consensus was compiled by experts from.Specialty Committee of Biotherapy the Chinese Research Hospital Association in November 2020,and was designed to provide more comprehensive and standardized treatment principles and exploratory theaputicopptions for clinical staff to identify and deal with the adverse events associated with CAR T cell therapy.

关 键 词：CAR T细胞 淋巴瘤 毒副作用 专家共识 

分 类 号：R733.1[医药卫生—肿瘤]